BridgeMD
New treatment option for Hip Osteoarthritis
Official title Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults
ClinicalTrials.gov ID: NCT07330999
What this study is testing
What is Ropivacaine 0.2% Injectable Solution?
Ropivacaine 0.2% Injectable Solution is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for hip osteoarthritis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study will compare three versions of the Pericapsular Nerve Group (PENG) block in adults aged 65 years and older who are undergoing hip surgery. The PENG block is a regional anesthesia technique used to reduce pain around the hip joint and may improve early recovery after surgery.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 to 100
You may be able to join if
- Age 65 years or older
- Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty)
- ASA physical status I-III
- Planned use of a PENG block as part of perioperative analgesia
- Ability to communicate pain intensity using the NRS scale
You likely can't join if
- Refusal or inability to provide informed consent
- Known allergy, intolerance, or contraindication to any of the study medications: ropivacaine, dexamethasone, dexmedetomidine
- Pre-existing neurological deficit or neuropathy in the affected limb
- Coagulopathy or laboratory abnormality that contraindicates regional anesthesia: INR \>1.5, or platelet count \<100,000/µL, or therapeutic...
- Infection at or near the needle insertion site
- Severe hepatic or renal impairment
See the full eligibility criteria
- Age 65 years or older
- Scheduled for elective or emergency hip surgery (e.g., hip fracture fixation or hip arthroplasty)
- ASA physical status I-III
- Planned use of a PENG block as part of perioperative analgesia
- Ability to communicate pain intensity using the NRS scale
- Written informed consent obtained from the patient or legal representative
- Refusal or inability to provide informed consent
- Known allergy, intolerance, or contraindication to any of the study medications: ropivacaine, dexamethasone, dexmedetomidine
- Pre-existing neurological deficit or neuropathy in the affected limb
- Coagulopathy or laboratory abnormality that contraindicates regional anesthesia: INR \>1.5, or platelet count \<100,000/µL, or therapeutic anticoagulation that cannot be safely paused
- Infection at or near the needle insertion site
- Severe hepatic or renal impairment
- Chronic opioid therapy (\>30 days of daily opioids before surgery)
- Cognitive impairment or delirium that prevents reliable pain assessment
- BMI \>40 kg/m² (due to potential technical difficulty and reduced accuracy of ultrasound guidance)
- Previous regional block affecting the target area for the current surgery
- Pregnancy or breastfeeding
- Participation in another treatment clinical trial within 30 days
The study team makes the final eligibility decision.
Where it's taking place
- Poznan, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poznan, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.